Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BBNX vs DCTH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DCTH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 6–3 Matrix Metrics)

DCTH Overall Winner 6-Pillar Tally: BBNX 0 – 6 DCTH Matrix Metrics: BBNX 3 – 6 DCTH

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Beta Bionics, Inc. (BBNX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BBNX carries a Unified Composite Score of 52.1/100 (HOLD) at $15.60 (N/M Forward P/E, -72.8% operating margin), whereas DCTH carries 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin).

  • Composite vs. Pillar Nuance: While BBNX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (6–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -72.8% operating margin) and revenue trajectory (+70.7% vs. +30.3% YoY).
  • Technical & Structure Timing Caution: BBNX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.7); meanwhile DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BBNX vs DCTH
BBNX NASDAQ
Beta Bionics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$15.60
-4.99% 1D
Market Cap $897.6M
TTM Revenue $127M
Forward P/E N/M
Beta / 30D Vol 1.83β · 108% Vol
Unified Composite Score
52.1 / 100 HOLD
Tech 51.0 Fund 59.0 Flow 57.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.1%), weak momentum, RSI 44
RSI-14: 43.7 · SMA20: $17.40 · SMA50: $18.40
DCTH NASDAQ Head-to-Head Winner
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$19.68
-4.23% 1D
Market Cap $743.8M
TTM Revenue $110M
Forward P/E N/M
Beta / 30D Vol 1.63β · 131% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 50.0 Fund 38.0 Flow 60.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 68.9 · SMA20: $16.43 · SMA50: $15.96

6-Pillar Scorecard Institutional Category Breakdown (BBNX 0 – 6 DCTH)

Columns: Metric · BBNX · DCTH
1. Valuation Multiples DCTH
Forward P/E N/M N/M
Trailing P/E N/M 133.6x
PEG Ratio N/M 1.60x
EV / Revenue 6.5x 6.3x
2. Growth & Scale DCTH
Revenue Growth (YoY) +30.3% +70.7%
Earnings Growth (YoY) +0.0% +750.0%
TTM Revenue (USD) $127M $110M
Market Cap $897.6M $743.8M
3. Profitability & Quality DCTH
Gross Margin 58.6% 87.6%
Operating Margin -72.8% 5.2%
Net Profit Margin -65.3% 6.0%
Return on Equity (ROE) -23.9% 5.4%
4. Balance Sheet & Cash Flow DCTH
Cash Generation (TTM) -$66M $20M
Cash Flow Margin -51.8% 18.3%
Net Cash / Leverage $75M Net Cash $53M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DCTH
Options Structure Phase CONSOLIDATION BREAKOUT
Current IV / %ile 217.1% (54th %ile) 109.3% (43rd %ile)
Put/Call OI Skew 0.02x (Call-Skewed) 0.11x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat DCTH
OpEx & R&D Intensity N/A 82.4% of Rev ($91M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BBNX (3) vs DCTH (6)
Institutional Metric BBNX DCTH Criterion Row Edge
Market Capitalization
Scale
$897.6M $743.8M Larger Scale BBNX
Trailing P/E Ratio
Valuation
N/M 133.6x Lower Multiple DCTH
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+30.3% +70.7% Higher Growth DCTH
Operating Margin (TTM)
Profitability
-72.8% 5.2% Higher Margin DCTH
Net Profit Margin
Profitability
-65.3% 6.0% Higher Margin DCTH
Return on Equity (ROE)
Capital Efficiency
-23.9% 5.4% Higher ROE DCTH
52-Week Range Position
Momentum
28% ($9–$33) 80% ($8–$23) Stronger Trend DCTH
Beta / 30D Volatility
Risk Regime
1.83β · 108% Vol 1.63β · 131% Vol Lower Realized Risk BBNX
Unified Institutional Score
Composite Signal
52.1 / 100 (HOLD) 35.9 / 100 (SELL) Higher Composite BBNX
Trailing 12M Revenue (USD)
Operating Scale
$127M $110M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
58.6% 87.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.5x EV/Rev 1.60x PEG · 6.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$66M ($75M Net Cash) $20M ($53M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DCTH +44.36 pp
BBNX: -4.59% · DCTH: +39.77%
3M Horizon DCTH +34.71 pp
BBNX: -17.98% · DCTH: +16.73%
6M Horizon DCTH +11.5 pp
BBNX: +65.96% · DCTH: +77.46%
1Y Horizon DCTH +169.12 pp
BBNX: -40.55% · DCTH: +128.57%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BBNX Revenue DCTH Revenue BBNX Op. Margin DCTH Op. Margin Margin Leader
FY2013 N/A $0M N/A -4179.6% DCTH
FY2014 N/A $0M N/A -1805.8% DCTH
FY2015 N/A $0M N/A -870.6% DCTH
FY2021 N/A $0M N/A -690.0% DCTH
FY2022 N/A $0M N/A -1245.1% DCTH
FY2023 $10M $0M -298.9% -1849.0% BBNX
FY2024 $70M $40M -69.5% -33.4% DCTH
FY2025 $100M $90M -71.5% 0.8% DCTH

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BBNX CONSOLIDATION
84d in phase · OBV NEUTRAL
Current IV 217.1%
IV Percentile 54th %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact BBNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DCTH BREAKOUT
66d in phase · OBV ACCUMULATION
Current IV 109.3%
IV Percentile 43rd %ile
Put/Call OI Skew 0.11x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BBNX Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $897.6M market capitalization and -72.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DCTH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $743.8M market capitalization and 5.2% operating margin.
OpEx & R&D Reinvestment 82.4% of Rev ($91M)
90D Engineering Disclosures 0 Published

Investor FAQ BBNX vs DCTH Key Questions & Quantitative Answers

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Beta Bionics, Inc. (BBNX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BBNX carries a Unified Composite Score of 52.1/100 (HOLD) at $15.60 (N/M Forward P/E, -72.8% operating margin), whereas DCTH carries 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin). Composite vs. Pillar Nuance: While BBNX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (6–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -72.8% operating margin) and revenue trajectory (+70.7% vs. +30.3% YoY). Technical & Structure Timing Caution: BBNX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.7); meanwhile DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DCTH leads the Growth & Scale pillar: BBNX posts +30.3% YoY revenue growth and +0.0% YoY earnings growth on $127M TTM revenue (58.6% gross margin, -72.8% operating margin), compared with DCTH at +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin). Across the 8-period historical trajectory (FY2013 to FY2025), BBNX cumulative revenue shifted +900.0% while DCTH shifted +125.0%. In operating R&D and SG&A reinvestment, BBNX deploys N/A (0 90-day corporate R&D disclosures) versus 82.4% of Rev ($91M) (0 disclosures) for DCTH.

DCTH screens cheaper on headline valuation multiples. BBNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.5x EV/Revenue (-51.8% FCF margin), whereas DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BBNX (-23.9% ROE) versus DCTH (5.4% ROE) capital efficiency.

In options market volatility and institutional positioning, BBNX carries 217.1% implied volatility (54th %ile, Balanced (25th–60th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.83β · 108% Vol realized risk). By comparison, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.